| Primary |
| Chronic Lymphocytic Leukaemia |
42.9% |
| Prophylaxis |
28.6% |
| Antibiotic Prophylaxis |
14.3% |
| Hypouricaemia |
14.3% |
|
| Drug Reaction With Eosinophilia And Systemic Symptoms |
50.0% |
| Hypertriglyceridaemia |
50.0% |
|
| Secondary |
| Product Used For Unknown Indication |
41.6% |
| Drug Use For Unknown Indication |
12.1% |
| Hiv Infection |
11.9% |
| Colon Cancer |
7.6% |
| Prophylaxis |
5.2% |
| Haemolytic Uraemic Syndrome |
2.4% |
| Eye Infection Toxoplasmal |
2.1% |
| Hypertension |
1.9% |
| Psoriasis |
1.9% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Toxoplasmosis |
1.7% |
| Hiv Test Positive |
1.5% |
| Antibiotic Prophylaxis |
1.3% |
| Aplasia |
1.3% |
| Hyperuricaemia |
1.1% |
| Antiretroviral Therapy |
0.9% |
| Colitis Ulcerative |
0.9% |
| Cytomegalovirus Infection |
0.9% |
| Osteitis |
0.9% |
| Rheumatoid Arthritis |
0.9% |
|
| Gait Disturbance |
15.4% |
| Thrombocytopenia |
10.8% |
| Hypertriglyceridaemia |
7.7% |
| Renal Colic |
7.7% |
| Toxic Skin Eruption |
7.7% |
| Nephrolithiasis |
6.2% |
| Rash Generalised |
6.2% |
| Tongue Oedema |
4.6% |
| Cardio-respiratory Arrest |
3.1% |
| Chest Pain |
3.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.1% |
| Memory Impairment |
3.1% |
| Rash Maculo-papular |
3.1% |
| Toxic Epidermal Necrolysis |
3.1% |
| Vertigo |
3.1% |
| Visceral Congestion |
3.1% |
| Vitamin B12 Deficiency |
3.1% |
| Convulsion |
1.5% |
| Dyskinesia |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.3% |
| Drug Use For Unknown Indication |
16.8% |
| Hiv Infection |
16.7% |
| Prophylaxis |
6.4% |
| Plasma Cell Myeloma |
3.5% |
| B-cell Lymphoma |
3.4% |
| Tuberculosis |
2.7% |
| Cerebral Toxoplasmosis |
2.7% |
| Chronic Lymphocytic Leukaemia |
2.4% |
| Mantle Cell Lymphoma |
2.4% |
| Multiple Myeloma |
1.9% |
| Hypertension |
1.7% |
| Pain |
1.7% |
| Anaemia |
1.5% |
| Drug Exposure During Pregnancy |
1.0% |
| Infection Prophylaxis |
1.0% |
| Constipation |
0.9% |
| Thrombosis Prophylaxis |
0.9% |
| Glioblastoma |
0.9% |
| Lung Disorder |
0.9% |
|
| Thrombocytopenia |
11.0% |
| Renal Failure Acute |
8.3% |
| Weight Decreased |
8.3% |
| Neutropenia |
7.3% |
| Pyrexia |
7.3% |
| Renal Tubular Disorder |
6.4% |
| Pancytopenia |
5.5% |
| Renal Failure |
5.5% |
| B-cell Lymphoma |
4.6% |
| Angioedema |
3.7% |
| Myelodysplastic Syndrome |
3.7% |
| Optic Neuropathy |
3.7% |
| Toxic Skin Eruption |
3.7% |
| Transplant Rejection |
3.7% |
| Viral Infection |
3.7% |
| Agranulocytosis |
2.8% |
| Bone Marrow Failure |
2.8% |
| Cholestasis |
2.8% |
| Febrile Bone Marrow Aplasia |
2.8% |
| Rash Morbilliform |
2.8% |
|
